SUPN

Supernus Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

31.700

+0.160(+0.510%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

32.220

Open

31.540

VWAP

31.70

Vol

474.19K

Mkt Cap

1.77B

Low

31.215

Amount

15.03M

EV/EBITDA(TTM)

7.89

Total Shares

54.97M

1.31B

EV/OCF(TTM)

7.99

P/S(TTM)

2.66

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

154.30M

-8.33%

0.500

-25.22%

158.01M

-10.06%

0.535

-51.23%

163.13M

-6.34%

0.610

+11.25%

Estimates Revision

The market is revising Upward the revenue expectations for Supernus Pharmaceuticals, Inc. (SUPN) for FY2025, with the revenue forecasts being adjusted by 0.37% over the past three months. During the same period, the stock price has changed by -16.42%.

Revenue Estimates for FY2025

Revise Upward

+0.37%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.77%

In Past 3 Month

Stock Price

Go Down

-16.42%

In Past 3 Month

5 Analyst Rating

22.40% Upside

Wall Street analysts forecast SUPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUPN is 38.80 USD with a low forecast of 36.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

22.40% Upside

Current: 31.700

Low

36.00

Averages

38.80

High

44.00

22.40% Upside

Current: 31.700

Low

36.00

Averages

38.80

High

44.00

Cantor Fitzgerald

Kristen Kluska

Hold

Reiterates

$36

2025-02-26

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$36

2025-02-26

Reiterates

Hold

Reason

Cantor Fitzgerald

Kristen Kluska

Buy

Hold

Downgrades

$57 → $36

2025-02-19

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$57 → $36

2025-02-19

Downgrades

Buy

Hold

Reason

Cantor Fitzgerald downgraded Supernus to Neutral from Overweight with a price target of $36, down from $57.

Piper Sandler

David Amsellem

Buy

Hold

Downgrades

$41 → $36

2024-09-11

Reason

Piper Sandler

David Amsellem

Price Target

$41 → $36

2024-09-11

Downgrades

Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Supernus Pharmaceuticals Inc (SUPN.O) is 14.68, compared to its 5-year average forward P/E of 21.41. For a more detailed relative valuation and DCF analysis to assess Supernus Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

21.41

Current PE

14.68

Overvalued PE

27.36

Undervalued PE

15.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

13.11

Current EV/EBITDA

5.95

Overvalued EV/EBITDA

19.16

Undervalued EV/EBITDA

7.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.69

Current PS

2.79

Overvalued PS

3.09

Undervalued PS

2.28